BCLXL PROTAC degrader DT2216 targets secondary plasma cell leukemia addicted to BCLXL for survival

Autor: Ophélie Champion, Alana Soler, Sophie Maïga, Céline Bellanger, Catherine Pellat-Deceunynck, Alexis Talbot, Cyrille Touzeau, Martine Amiot, Patricia Gomez-Bougie

Publikováno v: Frontiers in Oncology, Vol 13 (2023)

Secondary plasma cell leukemia (sPCL) is a rare form of aggressive plasma cell malignancy arising mostly at end-stage refractory multiple myeloma and consequently presenting limited therapeutic options. We analyzed 13 sPCL for their sensitivity to BH

Externí odkaz: https://doaj.org/article/730d127beed64625af783291e6a9514e

A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines

Autor: Jérôme Moreaux, Bernard Klein, Régis Bataille, Géraldine Descamps, Sophie Maïga, Dirk Hose, Hartmut Goldschmidt, Anna Jauch, Thierry Rème, Michel Jourdan, Martine Amiot, Catherine Pellat-Deceunynck

Publikováno v: Haematologica, Vol 96, Iss 4 (2011)

Background Multiple myeloma is a plasma-cell tumor with heterogeneity in molecular abnormalities and treatment response.Design and Methods We have assessed whether human myeloma cell lines have kept patients’ heterogeneity using Affymetrix gene exp

Externí odkaz: https://doaj.org/article/c4cb583bc965493b97d64e6a76020eea

TP53 CRISPR/Cas9 Reveals Strict BAX Dependence in the Response to BH3 Mimetic Targeting MCL1

Autor: Romane Durand, Domitille Costes-Tertrais, Geraldine Descamps, Christelle Dousset, Sophie Maïga, Jean-Baptiste Alberge, Elise Douillard, Jennifer Derrien, Celine Bellanger, David Chiron, Stephane Minvielle, Cyrille Touzeau, Philippe Moreau, Martine Amiot, Patricia Gomez-Bougie, Agnes Moreau-Aubry, Catherine Pellat-Deceunynck

Publikováno v: Blood. 140:4198-4199

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::68358fc5d38745cca0becedcd4afc4fe
https://doi.org/10.1182/blood-2022-155862

Dual targeting of BCL2 and MCL1 rescues myeloma cells resistant to BCL2 and MCL1 inhibitors associated with the formation of BAX/ BAK hetero-complexes

Autor: Charlotte Kervoëlen, Sophie Maïga, Patricia Gomez-Bougie, Carolane Seiller, Laurent Maillet, Celine Bellanger, Philippe Moreau, Martine Amiot, Catherine Pellat-Deceunynck, Géraldine Descamps, Cyrille Touzeau

Publikováno v: Cell Death and Disease
Cell Death and Disease, Nature Publishing Group, 2020, 11, pp.316. ⟨10.1038/s41419-020-2505-1⟩
Cell Death & Disease
Cell Death and Disease, Vol 11, Iss 5, Pp 1-14 (2020)
Cell Death and Disease, 2020, 11, pp.316. ⟨10.1038/s41419-020-2505-1⟩

Multiple myeloma is a plasma cell malignancy that escapes from apoptosis by heterogeneously over-expressing anti-apoptotic BCL2 proteins. Myeloma cells with a t(11;14) translocation present a particular vulnerability to BCL2 inhibition while a majori

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4e9644ed4a52b0d338eaf460f78963de
https://www.hal.inserm.fr/inserm-02563554/document

Decitabine and Melphalan Fail to Reactivate p73 in p53 Deficient Myeloma Cells

Autor: Steven Le Gouill, Benedetta Lucani, David Chiron, Philippe Moreau, Agnès Moreau-Aubry, Sophie Maïga, Benoit Tessoulin, Hanane Djamai, Géraldine Descamps, Martine Amiot, Pierre-Samuel Gillardin, Catherine Pellat-Deceunynck

Publikováno v: International Journal of Molecular Sciences, Vol 19, Iss 1, p 40 (2017)
International Journal of Molecular Sciences
International Journal of Molecular Sciences, 2017, 19 (1), ⟨10.3390/ijms19010040⟩
International Journal of Molecular Sciences, MDPI, 2017, 19 (1), ⟨10.3390/ijms19010040⟩

International audience; (1) Background: TP53 deficiency remains a major adverse event in Multiple Myeloma (MM) despite therapeutic progresses. As it is not possible to target TP53 deficiency with pharmacological agents, we explored the possibility of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::58498cce87fe2a27c9ac301bb4a6ff5b
https://www.mdpi.com/1422-0067/19/1/40